At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 182 enrolled
Drug / intervention
LY2127399biological
Likely dose
LY2127399 60 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
In Brief
A Phase 2 clinical trial evaluating LY2127399 for Rheumatoid Arthritis. Completed, enrolled 182 participants across 62 sites in 14 countries.
Detailed Summary
To evaluate the safety and tolerability of LY2127399 administered as subcutaneous injections for 48 weeks in participants with Rheumatoid Arthritis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesAustralia, Austria, Belgium, Brazil, Canada, Chile, Germany, Hungary, India, Mexico, Poland, Puerto Rico, Romania, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedFeb 2009
Primary CompletionJan 2011
Study CompletionJan 2012
TodayJul 2026
First PostedFeb 5, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJan 1, 2011
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.4 years ago
Interventions
LY2127399biological
60 milligrams \[(mg) with potential for dose escalation to 120 mg\] subcutaneously every 4 weeks for 48 weeks